# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k062379   
B. Purpose for Submission: New device   
C. Measurand: Assayed control for prealbumin and ceruloplasmin assays.   
D. Type of Test: Not applicable.   
E. Applicant: Roche Diagnostics Corp.   
F. Proprietary and Established Names: Prealbumin/Ceruloplasmin Control Set (Precinorm/Precipath

G. Regulatory Information:   

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JJY</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1660</td><td rowspan=1 colspan=1>Chemistry (75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): Prealbumin/Ceruloplasmin Control Set (Precinorm/Precipath PC) is used for quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.   
2. Indication(s) for use: Prealbumin/Ceruloplasmin Control Set (Precinorm/Precipath PC) is used for quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.   
3. Special conditions for use statement(s): Prescription use   
4. Special instrument requirements: COBAS INTEGRA and Roche/Hitachi family of analyzers.

# I. Device Description:

The Prealbumin/Ceruloplasmin Control Set (Precinorm/Precipath PC) is a lyophilized control based on human serum. The adjusted concentrations of the control components are usually in the normal range or at the normal/pathological threshold. Each Precinorm/Precipath PC Control Set contains 3 bottles of controls (a $1 . 0 \mathrm { m l }$ fill volume per bottle) at Levels I, and II. Individual donors units were tested by FDA approved methods for HBsAg, HCV and HIV and found to be nonreactive.

J. Substantial Equivalence Information:

<table><tr><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">K040280 Precinorm PUC</td></tr><tr><td colspan="2" rowspan="1">Describe the item being compared</td></tr><tr><td colspan="2" rowspan="1">Prealbumin/Ceruloplasmin Control Set (Precinorm/Precipath PC) is used for quality control bymonitoring accuracy and precision for the quantitative methods as specified in the enclosed valuesheet.</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Prealbumin/CeruloplasminControl Set(Precinorm/Precipath PC) isused for quality control bymonitoring accuracy andprecision for thequantitative methods asspecified in the enclosedvalue sheet</td><td colspan="1" rowspan="1">Precinorm PUC (Proteins inUrine/CSF) is for use inquality control bymonitoring accuracy andprecision for thequantitative methods asspecified in the enclosedvalue sheet</td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>New Device</td><td>Predicate</td></tr><tr><td>Matrix</td><td>Human serum based</td><td>Buffered aqueous solution</td></tr><tr><td>Format</td><td>Lyophilized</td><td>Liquid, ready to use</td></tr><tr><td>Handling</td><td>Reconstitute with exactly 1.0 mL of distilled water and allow to stand closed for 30 minutes to reconstitute, and then mix gently.</td><td>Ready to use.</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=2 colspan=1>Points to Consider Guidance Document onAssayed and Unassayed Quality ControlMaterial; Draft</td><td rowspan=2 colspan=1>OIVD</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/99.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

L. Test Principle:

Not applicable

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Not applicable b. Linearity/assay reportable range: Not applicable c. Traceability, Stability, Expected values (controls, calibrators, or methods): The Precinorm/Precipath Control Set products are assayed and traceable to the Institute for Reference Methods and Materials (IRMM). Values are assigned at three internal laboratories using the COBAS Integra and Roche Hitachi c systems. Each laboratory runs at least three independent series of analyses on each instrument for each analyte. Each sample is tested in singleton. The target value is then calculated as the median of the determined values. The following tables list lot-specific target values and ranges.

<table><tr><td rowspan=1 colspan=1>Precinorm PC</td><td rowspan=1 colspan=1>Target valueRoche/Hitachi systems</td><td rowspan=1 colspan=1>Target Value COBASINTEGRA systems</td></tr><tr><td rowspan=1 colspan=1>Ceruloplasmin</td><td rowspan=1 colspan=1>21.7-35.5 mg/dL</td><td rowspan=1 colspan=1>21.3-34.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Prealbumin</td><td rowspan=1 colspan=1>16.9-27.7 mg/dL</td><td rowspan=1 colspan=1>16.6-26.8 mg/dL</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Precipath</td><td rowspan=1 colspan=1>Target valueRoche/Hitachi systems</td><td rowspan=1 colspan=1>Target ValueCOBASINTEGRA systems</td></tr><tr><td rowspan=1 colspan=1>Ceruloplasmin</td><td rowspan=1 colspan=1>49.0-80.2 mg/dL</td><td rowspan=1 colspan=1>51.7-84.1</td></tr><tr><td rowspan=1 colspan=1>Prealbumin</td><td rowspan=1 colspan=1>39.6-64.8 mg/dL</td><td rowspan=1 colspan=1>40.6-66.4</td></tr></table>

The unopened products are stable for 18 months when stored at 2 to $8 \ : ^ { \mathrm { \circ } } \mathrm { C }$ . The following table lists the reconstituted products stability:

<table><tr><td rowspan=1 colspan=1>Temperature</td><td rowspan=1 colspan=1>Stability</td></tr><tr><td rowspan=1 colspan=1>15 - 25°C</td><td rowspan=1 colspan=1>up to 8 hours</td></tr><tr><td rowspan=1 colspan=1>2 - 8C</td><td rowspan=1 colspan=1>2 days</td></tr><tr><td rowspan=1 colspan=1>-15 to -25°C</td><td rowspan=1 colspan=1>2 weeks, freeze onlyonce</td></tr></table>

Protocols and acceptance criteria for stability testing were described and found to be acceptable.

d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable   
f. Assay cut-off: Not applicable

2. Comparison studies: a. Method comparison with predicate device: Not applicable b. Matrix comparison: Not applicable

3. Clinical studies: a. Clinical Sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.